Fisher Asset Management LLC Has $999,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Fisher Asset Management LLC boosted its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 88.9% in the fourth quarter, Holdings Channel reports. The firm owned 68,411 shares of the company’s stock after purchasing an additional 32,203 shares during the period. Fisher Asset Management LLC’s holdings in Day One Biopharmaceuticals were worth $999,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Day One Biopharmaceuticals by 8.1% during the third quarter. Vanguard Group Inc. now owns 4,629,754 shares of the company’s stock valued at $56,807,000 after purchasing an additional 346,090 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in shares of Day One Biopharmaceuticals by 38.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 447,138 shares of the company’s stock valued at $5,486,000 after buying an additional 125,050 shares during the period. Bank of New York Mellon Corp increased its position in shares of Day One Biopharmaceuticals by 22.4% during the third quarter. Bank of New York Mellon Corp now owns 220,296 shares of the company’s stock worth $2,703,000 after acquiring an additional 40,387 shares in the last quarter. TimesSquare Capital Management LLC raised its holdings in shares of Day One Biopharmaceuticals by 41.8% during the third quarter. TimesSquare Capital Management LLC now owns 1,142,610 shares of the company’s stock worth $14,020,000 after acquiring an additional 336,910 shares during the period. Finally, Deutsche Bank AG lifted its position in Day One Biopharmaceuticals by 5.5% in the 3rd quarter. Deutsche Bank AG now owns 177,137 shares of the company’s stock valued at $2,173,000 after acquiring an additional 9,219 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Down 0.2 %

DAWN opened at $16.38 on Friday. Day One Biopharmaceuticals, Inc. has a 12-month low of $9.67 and a 12-month high of $18.07. The business has a 50 day moving average of $15.45 and a 200-day moving average of $14.20. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -6.88 and a beta of -1.44.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its quarterly earnings data on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $34,434.50. Following the transaction, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel Adam Dubow sold 3,242 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $49,440.50. Following the completion of the transaction, the general counsel now owns 16,585 shares in the company, valued at $252,921.25. The disclosure for this sale can be found here. Insiders have sold a total of 195,247 shares of company stock worth $3,376,817 over the last ninety days. Insiders own 8.40% of the company’s stock.

Wall Street Analysts Forecast Growth

DAWN has been the topic of a number of research reports. JPMorgan Chase & Co. boosted their price target on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a report on Monday, April 22nd. Piper Sandler restated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Tuesday, March 26th. Oppenheimer reiterated a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. The Goldman Sachs Group reduced their price objective on shares of Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, February 27th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Day One Biopharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $37.67.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.